These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7448726)

  • 21. Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.
    Gonçalves A; Deblock M; Esterni B; Tarpin C; Bertucci F; Gilabert M; Charafe-Jauffret E; Jacquemier J; Houvenaeghel G; Extra JM; Viens P
    Anticancer Drugs; 2009 Nov; 20(10):946-52. PubMed ID: 19741502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized Feasibility Study of
    Chae SY; Kim SB; Ahn SH; Kim HO; Yoon DH; Ahn JH; Jung KH; Han S; Oh SJ; Lee SJ; Kim HJ; Son BH; Gong G; Lee HS; Moon DH
    J Nucl Med; 2017 Apr; 58(4):563-568. PubMed ID: 27688475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant chemotherapy in luminal breast cancers.
    Lim E; Winer EP
    Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current status of breast cancer chemotherapy in Japan.
    Koyama H
    Recent Results Cancer Res; 1980; 70():159-66. PubMed ID: 6243785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer.
    Kiang DT; Gay J; Goldman A; Kennedy BJ
    N Engl J Med; 1985 Nov; 313(20):1241-6. PubMed ID: 3903501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?
    Pritchard KI
    Breast Cancer Res Treat; 2011 Jun; 127(2):587-8. PubMed ID: 19191022
    [No Abstract]   [Full Text] [Related]  

  • 28. Combination therapy of hormone and cytotoxic agents in advanced breast cancer.
    Kiang DT; Frenning DH; Gay J; Goldman AI; Kennedy BJ
    Cancer; 1981 Feb; 47(3):452-6. PubMed ID: 7013960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Correlations between hormonal receptor and HER2 status or nuclear grades and response rate in breast cancer treated with neoadjuvant chemotherapy of docetaxel alone].
    Mimae T; Taira N; Ohsumi S; Takabatake D; Takashima S; Aogi K; Takashima S; Nishimura R
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):619-22. PubMed ID: 19381035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen receptors and breast cancer: prognostic and therapeutic implications.
    Gapinski PV; Donegan WL
    Surgery; 1980 Sep; 88(3):386-93. PubMed ID: 7414516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.
    Bertelli G; Garrone O; Bertolotti L; Occelli M; Conforti S; Marzano N; Febbraro A; Carlini P; Liossi C; Del Mastro L; Leonard RC
    Oncology; 2005; 68(4-6):364-70. PubMed ID: 16020964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sensitivity of chemotherapy depending on hormone status in breast cancer].
    Ito Y
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():568-71. PubMed ID: 17679212
    [No Abstract]   [Full Text] [Related]  

  • 35. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
    Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
    J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.
    Montemurro F; Aglietta M
    Endocr Relat Cancer; 2009 Dec; 16(4):1091-102. PubMed ID: 19726539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between primary breast tumor receptor status and patient survival.
    Blamey RW; Bishop HM; Blake JR; Doyle PJ; Elston CW; Haybittle JL; Nicholson RI; Griffiths K
    Cancer; 1980 Dec; 46(12 Suppl):2765-9. PubMed ID: 7448717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.